Principal Financial Group
RCUS icon

Principal Financial Group’s Arcus Biosciences RCUS Stock Holding History

Principal Financial Group’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$11.3M Buy
439,195
+15,829
+4% +$446K 0.01% 1342
2026
Q2 		$13.1M Buy
423,366
+9,588
+2% +$237K 0.01% 1261
2026
Q1 		$8.94M Buy
413,778
+6,265
+2% +$135K ﹤0.01% 1385
2025
Q4 		$9.7M Buy
407,513
+72,989
+22% +$1.49M 0.01% 1334
2025
Q3 		$4.55M Sell
334,524
-1,701
-0.5% -$17.7K ﹤0.01% 1624
2025
Q2 		$2.74M Buy
336,225
+1,244
+0.4% +$10.6K ﹤0.01% 1747
2025
Q1 		$2.63M Buy
334,981
+71,464
+27% +$829K ﹤0.01% 1724
2024
Q4 		$3.92M Buy
263,517
+7,906
+3% +$129K ﹤0.01% 1663
2024
Q3 		$3.91M Sell
255,611
-18,777
-7% -$296K ﹤0.01% 1636
2024
Q2 		$4.18M Sell
274,388
-15,577
-5% -$251K ﹤0.01% 1595
2024
Q1 		$5.47M Sell
289,965
-42,849
-13% -$741K ﹤0.01% 1536
2023
Q4 		$6.36M Buy
332,814
+3,372
+1% +$53.9K ﹤0.01% 1478
2023
Q3 		$5.91M Buy
329,442
+1,312
+0.4% +$26.4K ﹤0.01% 1465
2023
Q2 		$6.66M Buy
328,130
+3,390
+1% +$64.6K ﹤0.01% 1426
2023
Q1 		$5.92M Sell
324,740
-4,267
-1% -$81.6K ﹤0.01% 1480
2022
Q4 		$6.8M Sell
329,007
-12,199
-4% -$336K 0.01% 1424
2022
Q3 		$8.93M Buy
341,206
+9,429
+3% +$249K 0.01% 1248
2022
Q2 		$8.41M Buy
331,777
+323,465
+3,892% +$7.92M 0.01% 1347
2022
Q1 		$262K Sell
8,312
-268
-3% -$8.98K ﹤0.01% 2272
2021
Q4 		$347K Sell
8,580
-5,499
-39% -$213K ﹤0.01% 2211
2021
Q3 		$491K Sell
14,079
-2,283
-14% -$71.1K ﹤0.01% 2176
2021
Q2 		$449K Sell
16,362
-7,052
-30% -$201K ﹤0.01% 2240
2021
Q1 		$657K Sell
23,414
-666
-3% -$23.2K ﹤0.01% 2085
2020
Q4 		$625K Buy
+24,080
New +$583K ﹤0.01% 2055

Other funds holding RCUS

Gilead Sciences
Gilead Sciences Foster City, California $1.46B AUM 71.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Principal Financial Group's RCUS Position: Q3 2026 in Review

Principal Financial Group increased its Arcus Biosciences (RCUS) stake by 3.7% in Q3 2026, buying an estimated $446K and bringing the position to 439,195 shares worth $11.3M. The position accounts for 0.01% of the portfolio, ranked #1342.

Principal Financial Group first reported a position in RCUS in Q4 2020 and has held it in 24 quarters since. The position peaked at $13.1M in Q2 2026. 171 funds tracked by Wall St. Rank hold RCUS as of Q3 2026.

  • Principal Financial Group held 439,195 shares of Arcus Biosciences worth $11.3M as of Q3 2026.
  • Principal Financial Group bought 15,829 Arcus Biosciences shares in Q3 2026, an estimated $446K.
  • Arcus Biosciences made up 0.01% of Principal Financial Group's portfolio in Q3 2026, its #1342 holding.
  • Principal Financial Group first reported a position in Arcus Biosciences in Q4 2020 and has held it in 24 quarters since.
  • Principal Financial Group's Arcus Biosciences position peaked at $13.1M in Q2 2026.
  • 171 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2026.

Based on Principal Financial Group's 13F filing for Q3 2026, filed 2 Nov 2026.